Genesis Molecular AI
Genesis Molecular AI is developing advanced software tools for drug discovery, combining machine learning, simulation, and computational chemistry to accelerate the development of new medicines.
Genesis Molecular AI is a biotechnology company delivering the industry’s most advanced molecular AI platform to unlock tough protein targets and accelerate drug discovery at scale. Its platform combines AI-driven analytics with molecular understanding to identify viable targets and design candidate medicines more efficiently. The solution is tailored for biotech and pharmaceutical teams seeking scalable, data-driven discovery workflows that shorten preclinical timelines. Genesis positions itself as a leader in AI-enabled drug discovery, helping researchers move faster from target to medicine.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Genesis Molecular AI.
64% above the average for this role
Senior Scientist, Computational Chemistry
lifelancer
Director, Computational Sciences
AbbVie
Computational Chemist
Variational AI
Postdoc in Computational Molecular Design of Mixed Matrix Membranes - DTU Chemical Engineering
Oracle
Computational Chemistry Scientist
Roche
Computer Aided Drug Design, AI/ML Expert
Diversity Employment